纵向Tau-PET累积模式对阿尔茨海默病临床试验设计的启示
本研究基于TRIAD和ADNI两个纵向队列,分析542名参与者(321名非AD对照,221名AD患者)按Alzheimer协会生物学分期(A+T2-、A+T2MTL+、A+T2MOD+、A+T2HIGH+)的纵向Tau-PET累积模式。结果显示Tau累积的区域分布和幅度取决于基线AD分期,且根据分期选择感兴趣区域可将检测疾病修饰药物效应所需样本量降低30%-93%。
要点
- 基线生物学AD分期决定Tau-PET纵向累积的区域和幅度。
- A+T2-个体在4-6年内无显著Tau累积,早期AD累积局限于早期受累区域。
- 分期特异性选择Tau-PET感兴趣区域可降低所需样本量30%-93%。
核心结论
- 基线生物学AD分期对选择Tau-PET结局感兴趣区域至关重要。
- 将结局区域与疾病分期匹配可降低样本量估计,可能提高试验效率。
研究设计与样本
- 回顾性分析TRIAD和ADNI两个纵向 observational 队列的数据。
- 纳入542名参与者,平均年龄67.9±15.3岁,女性56.3%,其中非AD对照321名,AD患者221名。
- 参与者接受淀粉样蛋白PET和Tau-PET成像,平均随访2.96±1.35年。
- 采用线性混合效应模型评估分期特异性区域纵向Tau-PET变化,并进行统计功效分析。
主要发现
- A+T2-个体在4-6年内无显著Tau累积。
- 早期AD患者Tau累积局限于早期受累区域(TRIAD: β=0.15, 95%CI 0.09-0.21, p<0.001;ADNI: β=0.21, 95%CI 0.03-0.40, p=0.03)。
- 中期AD患者累积于中间区域(TRIAD: β=0.16, 95%CI 0.10-0.22, p<0.001;ADNI: β=0.37, 95%CI 0.15-0.59, p=0.001)。
- 晚期AD患者累积于后期受累区域(TRIAD: β=0.45, 95%CI 0.39-0.50, p<0.001;ADNI: β=0.31, 95%CI 0.14-0.49, p<0.001)。
- 分期特异性选择Tau-PET感兴趣区域可将检测假设性疾病修饰药物效应所需样本量降低30%-93%。
关键数值与推荐
- 根据Tau-PET摄取将淀粉样蛋白PET阳性参与者分为A+T2-(初始)、A+T2MTL+(早期)、A+T2MOD+(中期)、A+T2HIGH+(晚期)。
- 淀粉样蛋白PET阴性参与者作为非AD对照。
临床怎么用
- 在AD临床试验中,应根据基线生物学AD分期选择Tau-PET结局感兴趣区域。
- 匹配结局区域与疾病分期可能减少所需样本量,提高试验效率。
局限性
- 两个独立队列使用的示踪剂和人口学构成存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Tau-PET is increasingly used in Alzheimer disease (AD) clinical trials, both for participant selection based on disease stage and as an outcome measure. However, the longitudinal patterns of tau accumulation according to AD stages remain unclear. We aimed to examine the patterns of tau-PET accumulation in different AD stages defined by the Alzheimer's Association Workgroup to inform trial design. METHODS: This was a retrospective analysis of data collected from participants in 2 longitudinal observational cohort studies: the Translational Biomarkers in Aging and Dementia (TRIAD) study from Montreal, Canada, and Alzheimer's Disease Neuroimaging Initiative (ADNI), a multisite study in North America. Amyloid-PET-positive participants were biologically staged as one of the following based on tau-PET uptake: A+T2- (initial), A+T2MTL+ (early), A+T2MOD+ (intermediate), and A+T2HIGH+ (advanced). Amyloid-PET-negative participants were included as non-AD controls. All participants underwent amyloid-PET and tau-PET imaging, with longitudinal follow-up (mean: 2.96 ± 1.35 years). Linear mixed-effects models evaluated stage-specific regional longitudinal tau-PET changes; statistical power analyses estimated the sample sizes needed to detect differences in tau-PET accumulation for future AD trials. RESULTS: The study included 542 participants (mean age: 67.9 ± 15.3 years; 56.3% female), comprising 321 non-AD controls and 221 individuals with AD. The baseline AD stage determined both the regional distribution and magnitude of tau accumulation. No significant accumulation occurred in A+T2- individuals over 4-6 years. In those with early-stage AD, tau accumulation was localized to early affected regions (TRIAD: β = 0.15, 95% CI 0.09-0.21, p < 0.001; ADNI: β = 0.21, 95% CI 0.03-0.40, p = 0.03). Individuals with intermediate-stage AD showed accumulation in intermediate regions (TRIAD: β = 0.16, 95% CI 0.10-0.22, p < 0.001; ADNI: β = 0.37, 95% CI 0.15-0.59, p = 0.001) while those with advanced-stage AD exhibited accumulation in later affected regions (TRIAD: β = 0.45, 95% CI 0.39-0.50, p < 0.001; ADNI: β = 0.31, 95% CI 0.14-0.49, p < 0.001). Stage-specific tau-PET region-of-interest selection reduced required sample sizes by 30%-93% for detecting hypothetical disease-modifying drug effects. DISCUSSION: Stage-specific patterns of tau-PET change highlighted the importance of baseline biological AD staging for selecting outcome regions of interest. Statistical power analyses indicated that aligning outcome regions with disease stage reduced sample size estimates, suggesting potential gains in trial efficiency. While findings were consistent across 2 independent cohorts, differences in tracers and demographic composition represent key limitations.
引用
- Trudel L, Therriault J, Macedo AC, et al. Implication for Clinical Trials From Longitudinal Tau-PET Accumulation Across Biological Alzheimer Disease Stages. Neurology. 2025. PMID: 40986433. doi:10.1212/WNL.0000000000214111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。